trending Market Intelligence /marketintelligence/en/news-insights/trending/DNpRd3TIzx39SulFNcdUGg2 content esgSubNav
In This List

Zynerba Pharmaceuticals stock plummets as epilepsy drug fails phase 2 trial

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Zynerba Pharmaceuticals stock plummets as epilepsy drug fails phase 2 trial

Zynerba Pharmaceuticals Inc. said its epilepsy drug ZYN002 failed to meet its endpoints in a phase 2 trial.

The company was determining whether the cannabidiol gel could reduce the frequency of seizures in adult patients who were enrolled in the trial when compared to placebo.

Zynerba Pharmaceuticals shares were down nearly 59% to $6.19 as of 11:12 a.m. ET on Aug. 7.

The setback is not the end of the therapy though. The gel is also being investigated in patients with osteoarthritis and children with the Fragile X syndrome, with phase 2 clinical trial results expected in August and September, respectively.